{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:00:10Z","timestamp":1740106810492,"version":"3.37.3"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T00:00:00Z","timestamp":1748131200000},"content-version":"am","delay-in-days":328,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA024022","UG3DA050311"],"award-info":[{"award-number":["R01DA024022","UG3DA050311"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.bioorg.2024.107489","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T16:07:01Z","timestamp":1716394021000},"page":"107489","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Blocking potential metabolic sites on NAT to improve its safety profile while retaining the pharmacological profile"],"prefix":"10.1016","volume":"148","author":[{"given":"Rachael","family":"Flammia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boshi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piyusha P.","family":"Pagare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celsey","family":"M. St. Onge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3539-7496","authenticated-orcid":false,"given":"Abeje","family":"Abebayehu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James C.","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rolando E.","family":"Mendez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3118-9339","authenticated-orcid":false,"given":"Dana E.","family":"Selley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William L.","family":"Dewey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8934-7016","authenticated-orcid":false,"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2023","series-title":"Opioid Addiction","author":"Azadfard","key":"10.1016\/j.bioorg.2024.107489_b0005"},{"key":"10.1016\/j.bioorg.2024.107489_b0010","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Fifth Edition.; American Psychiatric Publishing: Arlington, VA 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"10.1016\/j.bioorg.2024.107489_b0015","unstructured":"CDC. Understanding the Opioid Overdose Epidemic. https:\/\/www.cdc.gov\/opioids\/basics\/epidemic.html (accessed 2023-10-31)."},{"key":"10.1016\/j.bioorg.2024.107489_b0020","unstructured":"CDC. Opioid Overdose. https:\/\/www.cdc.gov\/drugoverdose\/deaths\/opioid-overdose.html (accessed 2023-10-31)."},{"key":"10.1016\/j.bioorg.2024.107489_b0025","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1146\/annurev-pharmtox-032112-135923","article-title":"Structure-function of the G protein-coupled receptor superfamily","volume":"53","author":"Katritch","year":"2013","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bioorg.2024.107489_b0030","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1021\/acschemneuro.7b00090","article-title":"Recent advances in the realm of allosteric modulators for opioid receptors for future therapeutics","volume":"8","author":"Remesic","year":"2017","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bioorg.2024.107489_b0035","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/ALN.0b013e318238bba6","article-title":"Molecular mechanisms of opioid receptor-dependent signaling and behavior","volume":"115","author":"Al-Hasani","year":"2011","journal-title":"Anesthesiology"},{"key":"10.1016\/j.bioorg.2024.107489_b0040","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1146\/annurev.pharmtox.40.1.389","article-title":"Molecular mechanisms and regulation of opioid receptor signaling","volume":"40","author":"Law","year":"2000","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.bioorg.2024.107489_b0045","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1046\/j.1471-4159.1995.64062534.x","article-title":"Expression of the Mu-opioid receptor in CHO cells: Ability of Mu-opioid ligands to promote alpha-azidoanilido[32P]GTP labeling of multiple G protein alpha subunits","volume":"64","author":"Chakrabarti","year":"1995","journal-title":"J. Neurochem."},{"key":"10.1016\/j.bioorg.2024.107489_b0050","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1046\/j.1365-2826.2003.01076.x","article-title":"Mu-opioid receptor modulates peptide release from rat neurohypophysial terminals by inhibiting Ca(2+) influx","volume":"15","author":"Ortiz-Miranda","year":"2003","journal-title":"J. Neuroendocrinol."},{"key":"10.1016\/j.bioorg.2024.107489_b0055","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/0024-3205(82)90180-1","article-title":"Receptor-related interactions of opiates with PGE-induced adenylate cyclase in brain","volume":"31","author":"Barchfeld","year":"1982","journal-title":"Life Sci."},{"key":"10.1016\/j.bioorg.2024.107489_b0060","article-title":"IUPHAR review: Recent progress in the development of Mu opioid receptor modulators to treat opioid use disorders","volume":"199","author":"Pagare","year":"2023","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bioorg.2024.107489_b0065","unstructured":"National Academies of Sciences, Engineering, and Medicine. 2019.Medications for opioid use disorder save lives. Washington, DC: The National Academies Press. (accessed 2024-01-17)."},{"key":"10.1016\/j.bioorg.2024.107489_b0070","unstructured":"Medications for Substance Use Disorders. https:\/\/www.samhsa.gov\/medications-substance-use-disorders (accessed 2023-10-09)."},{"key":"10.1016\/j.bioorg.2024.107489_b0075","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1021\/jacs.8b09756","article-title":"Chemical Interventions for the Opioid Crisis: Key Advances and Remaining Challenges","volume":"141","author":"Olson","year":"2019","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.bioorg.2024.107489_b0080","article-title":"Methadone Maintenance Therapy versus No Opioid Replacement Therapy for Opioid Dependence","author":"Mattick","year":"2003","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bioorg.2024.107489_b0085","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003409.pub3","article-title":"Methadone at Tapered Doses for the Management of Opioid Withdrawal","author":"Amato","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bioorg.2024.107489_b0090","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.biopsych.2019.06.020","article-title":"Medication Treatment of Opioid Use Disorder","volume":"87","author":"Bell","year":"2020","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.bioorg.2024.107489_b0095","first-page":"CD002207","article-title":"Buprenorphine Maintenance versus Placebo or Methadone Maintenance for Opioid Dependence","volume":"3","author":"Mattick","year":"2004","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.bioorg.2024.107489_b0100","first-page":"1506","article-title":"Injectable Extended-Release Naltrexone for Opioid Dependence: A Double-Blind, Placebo-Controlled","volume":"377","author":"Krupitsky","year":"2011","journal-title":"Multicentre Randomised Trial. Lancet"},{"key":"10.1016\/j.bioorg.2024.107489_b0105","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1505409","article-title":"Extended-Release Naltrexone to Prevent Opioid Relapse in Criminal Justice Offenders","volume":"374","author":"Lee","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bioorg.2024.107489_b0110","doi-asserted-by":"crossref","first-page":"365","DOI":"10.3109\/00952997509005662","article-title":"Clinical Experience with Naltrexone","volume":"2","author":"O\u2019Brien","year":"1975","journal-title":"Am. J. Drug Alcohol Abuse"},{"year":"2023","series-title":"Naltrexone","author":"Singh","key":"10.1016\/j.bioorg.2024.107489_b0115"},{"key":"10.1016\/j.bioorg.2024.107489_b0120","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1021\/acs.jmedchem.2c00087","article-title":"Design, synthesis, and biological evaluation of NAP isosteres: a switch from peripheral to central nervous system acting mu-opioid receptor antagonists","volume":"65","author":"Pagare","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107489_b0125","doi-asserted-by":"crossref","first-page":"6405","DOI":"10.1016\/j.bmc.2013.08.042","volume":"21","author":"Zaidi","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107489_b0130","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1016\/j.bmc.2017.03.005","article-title":"Binding mode analyses of NAP derivatives as mu opioid receptor selective ligands through docking studies and molecular dynamics simulation","volume":"25","author":"Wang","year":"2017","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107489_b0135","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1021\/jm801272c","article-title":"Design, synthesis, and biological evaluation of 6\u03b1- and 6\u03b2-N-heterocyclic substituted naltrexamine derivatives as \u03bc opioid receptor selective antagonists","volume":"52","author":"Li","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107489_b0140","doi-asserted-by":"crossref","first-page":"11399","DOI":"10.1021\/acs.jmedchem.9b01767","article-title":"Application of bivalent bioisostere concept on design and discovery of potent opioid receptor modulators","volume":"62","author":"Ma","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107489_b0145","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1021\/acschemneuro.8b00349","article-title":"Structure\u2212activity relationship studies of 6\u03b1- and 6\u03b2-indolylacetamidonaltrexamine derivatives as bitopic Mu opioid receptor modulators and elaboration of the \u201cmessage-address concept\u201d to comprehend their functional con-version","volume":"10","author":"Obeng","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bioorg.2024.107489_b0150","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1016\/j.bmc.2015.02.055","article-title":"Design, syntheses, and pharmacological characterization of 17-cyclopropyl-methyl-3,14\u03b2-dihydroxy-4,5\u03b1-epoxy-6\u03b1-(isoquinoline-3\u2032-carboxamido)morphinan analogues as opioid receptor ligands","volume":"23","author":"Yuan","year":"2015","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107489_b0155","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1021\/acs.jmedchem.8b01158","article-title":"Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14\u03b2-Dihydroxy-4,5\u03b1-Epoxy-6\u03b2-[(4\u2019-Pyridyl)Carboxamido]Morphinan (NAP) Derivatives as \u03bc\/\u03ba Opioid Receptor Dual Selective Ligands","volume":"62","author":"Zheng","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107489_b0160","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejphar.2018.03.013","article-title":"In Vitro and in Vivo Functional Profile Characterization of 17-Cyclopropylmethyl-3,14\u03b2-Dihydroxy-4,5\u03b1-Epoxy-6\u03b1-(Isoquinoline-3-Carboxamido)Morphinan (NAQ) as a Low Efficacy Mu Opioid Receptor Modulator","volume":"827","author":"Obeng","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bioorg.2024.107489_b0165","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1124\/dmd.111.038588","article-title":"Preclinical Disposition (in Vitro) of Novel \u03bc-Opioid Receptor Selective Antagonists","volume":"39","author":"Mitra","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.bioorg.2024.107489_b0170","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00213-014-3719-7","article-title":"Effects of the Novel, Selective and Low-Efficacy Mu Opioid Receptor Ligand NAQ on Intracranial Self-Stimulation in Rats","volume":"232","author":"Altarifi","year":"2015","journal-title":"Psychopharmacol. (berl)"},{"key":"10.1016\/j.bioorg.2024.107489_b0175","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1021\/acsptsci.2c00178","article-title":"Preclinical Characterization and Development on NAQ as a Mu Opioid Receptor Partial Agonist for Opioid Use Disorder Treatment","volume":"5","author":"Pagare","year":"2022","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.bioorg.2024.107489_b0180","doi-asserted-by":"crossref","first-page":"5045","DOI":"10.1016\/j.bmcl.2013.07.043","volume":"23","author":"Yuan","year":"2013","journal-title":"Bioorg Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107489_b0185","doi-asserted-by":"crossref","first-page":"9156","DOI":"10.1021\/jm4012214","article-title":"Design, Synthesis, and Biological Evaluation of 14-Heteroaromatic-Substituted Naltrexone Derivatives: Pharmacological Profile Switch from Mu Opioid Receptor Selectivity to Mu\/Kappa Opioid Receptor Dual Selectivity","volume":"56","author":"Yuan","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107489_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104702","article-title":"Verifying the Role of 3-Hydroxy of 17-Cyclopropylmethyl-4,5\u03b1-Epoxy-3,14\u03b2-Dihydroxy-6\u03b2-[(4\u2019-Pyridyl) Carboxamido]Morphinan Derivatives via Their Binding Affinity and Selectivity Profiles on Opioid Receptors","volume":"109","author":"Huang","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2024.107489_b0195","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1021\/acschemneuro.9b00038","article-title":"Characterization of 17-Cyclopropylmethyl-3,14\u03b2-Dihydroxy-4,5\u03b1-Epoxy-6\u03b1-(Indole-7-Carboxamido)Morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment","volume":"10","author":"Obeng","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bioorg.2024.107489_b0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.127953","article-title":"Exploring Naltrexamine Derivatives Featuring Azaindole Moiety via Nitrogen-Walk Approach to Investigate Their in Vitro Pharmacological Profiles at the Mu Opioid Receptor","volume":"41","author":"Ma","year":"2021","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2024.107489_b0205","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1021\/acs.jmedchem.2c01499","article-title":"Structural Alterations of the \u201cAddress\u201d Moiety of NAN Leading to the Discovery of a Novel Opioid Receptor Modulator with Reduced hERG Toxicity","volume":"66","author":"Ma","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107489_b0210","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1021\/tx100386z","article-title":"Bioactivation of substituted thiophenes including \u03b1-Chlorothiophene-Containing Compounds in Human Liver Microsomes","volume":"24","author":"Chen","year":"2011","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.bioorg.2024.107489_b0215","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1126\/science.3016896","article-title":"Psychotomimesis mediated by kappa opiate receptors","volume":"233","author":"Pfeiffer","year":"1986","journal-title":"Science."},{"key":"10.1016\/j.bioorg.2024.107489_b0220","doi-asserted-by":"crossref","unstructured":"Knoll, A. T.; Carlezon, W. A., Jr.; Dynorphin, stress, and depression.Brain Res.2010, 1314, 56\u201373. DOI: 10.1016\/j.brainres.2009.09.074.","DOI":"10.1016\/j.brainres.2009.09.074"},{"key":"10.1016\/j.bioorg.2024.107489_b0225","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/ph12020095","article-title":"Therapeutic Potential of Kappa Opioid Agonists","volume":"2","author":"Beck","year":"2019","journal-title":"Pharmaceuticals (basel)."},{"key":"10.1016\/j.bioorg.2024.107489_b0230","doi-asserted-by":"crossref","first-page":"4193","DOI":"10.1021\/acs.jmedchem.9b00378","article-title":"Dual Pharmacophores Explored via Structure-Activity Relationship (SAR) Matrix: Insights into Potent, Bifunctional Opioid Ligand Design","volume":"62","author":"Nastase","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107489_b0235","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1021\/acschemneuro.8b00363","article-title":"Synthesis and Biological Evaluation of Fentanyl Analogues Modified at Phenyl Groups with Alkyls","volume":"10","author":"Qin","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bioorg.2024.107489_b0240","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1021\/acschemneuro.8b00139","article-title":"Synthesis and Pharmacological Evaluation of Novel C-8 Substituted Tetrahydroquinolines as Balanced-Affinity Mu\/Delta Opioid Ligands for the Treatment of Pain","volume":"9","author":"Nastase","year":"2018","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.bioorg.2024.107489_b0245","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1517\/14740338.6.2.125","article-title":"Naloxone Treatment in Opioid Addiction: The Risks and Benefits","volume":"6","author":"van Dorp","year":"2007","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.bioorg.2024.107489_b0250","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature10954","article-title":"Crystal structure of the mu-opioid receptor bound to a morphinan antagonist","volume":"485","author":"Manglik","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2024.107489_b0255","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bioorg.2024.107489_b0260","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1016\/0024-3205(83)90103-0","article-title":"Naloxone hyperalgesia and stress-induced analgesia in rats","volume":"32","author":"Coderre","year":"1983","journal-title":"Life Sci."},{"key":"10.1016\/j.bioorg.2024.107489_b0265","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.ejmech.2006.12.037","article-title":"The consequences of scoring docked ligand conformations using free energy correlations","volume":"42","author":"Spyrakis","year":"2007","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107489_b0270","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/cbdv.200490016","article-title":"The importance of being exhaustive. Optimization of bridging structural water molecules and water networks in models of biological systems","volume":"1","author":"Kellogg","year":"2004","journal-title":"Chem. Biodiversity"},{"key":"10.1016\/j.bioorg.2024.107489_b0275","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1016\/j.bmc.2007.11.076","article-title":"Docking and hydropathic scoring of polysubstituted pyrrole compounds with antitubulin activity","volume":"16","author":"Tripathi","year":"2008","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.bioorg.2024.107489_b0280","doi-asserted-by":"crossref","unstructured":"Kellogg, G. E.; Abraham, D. J. Hydrophobicity: is LogPo\/w more than the sum of its parts? Eur. J. Med. Chem. 2007, 42, 921-933. 2000, 35, 651-661. DOI: 10.1016\/S0223-5234(00)00167-7.","DOI":"10.1016\/S0223-5234(00)00167-7"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824003948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0045206824003948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T19:17:21Z","timestamp":1717615041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0045206824003948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":56,"alternative-id":["S0045206824003948"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107489","relation":{},"ISSN":["0045-2068"],"issn-type":[{"type":"print","value":"0045-2068"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blocking potential metabolic sites on NAT to improve its safety profile while retaining the pharmacological profile","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2024.107489","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107489"}}